Details for the presentations are as follows: Title: Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors Presentation Number: 1256MO Session Category: Mini oral session Session Title: NSCLC metastatic Presentation Date and Time: Saturday September 14, 2024, 10:30 – 10:35 CEST Location: Santander Auditorium – Hall 5 Presenter: Benjamin Besse, M.D., Ph.D. (Institut Gustav Roussy, Villejuif, France) Title: Profiling of Zidesamtinib and Other ROS1 Inhibitors in an Intracranial ...

CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that Henry Pelish, Ph.D., has been promoted to Chief Scientific Officer. In this role, Dr. Pelish will continue to oversee discovery and early-stage development activities. Dr. Pelish contributed to the creation of Nuvalent and joined as Biology lead in 2018, overseeing the di ...

Nuvalent (NASDAQ:NUVL) recently publicized that the FDA gave NVL-655 their Breakthrough Therapy Designation (BTD) for locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC). The BTD press release encouraged me to do some preliminary research on Nuvalent and NVL-655. It didn't take me long to determine that NVL-655 has the potential to be a vital therapy for ALK+ NSCLC patients who often have to deal with multiple lines of therapy after their cancer develops resistance to targeted therapy aft ...

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing ...

CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or metastatic ALK- positive non-small cell lung cancer (NSCLC) who have been previously treated with two or more AL ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-40671 NUVALENT, INC. (Exact Name of Registrant as Specified in its Charter) Delawar ...

Exhibit 99.1 Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical meeting in the second half of 2024 Strong financial position with operating runway anticipated into 2027 CAMBRIDGE, Mass. — May 9, 2024 — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically pr ...

Investors are always looking for stocks that are poised to beat at earnings season and Nuvalent, Inc. (NUVL) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Nuvalent is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR Commission file number: 001-40671 NUVALENT, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) One Broadway, 14 Floor th Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) (857) 357-7000 ☐ TRA ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-40671 NUVALENT, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5112298 (State or other jurisdiction of incorporation or organization) One Broadway, 14 Floo ...